Blood test may predict when breast cancer drugs fail

NCT ID NCT06388122

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 32 times

Summary

This study looks at whether a blood test called DiviTumTKa can help doctors know early on if a treatment for hormone-receptor-positive (HR+) metastatic breast cancer is no longer working. About 100 people starting or continuing standard therapies (endocrine therapy with or without a CDK4/6 inhibitor) will give blood samples over time. The goal is to see if rising levels of a marker called thymidine kinase activity (TKa) can predict treatment resistance within 6 months, which could help guide future care decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.